What is the recommended management for a patient with Wilson disease complicated by portal hypertension, ascites, and cirrhosis?

Management of Wilson Disease with Portal Hypertension, Ascites, and Cirrhosis

Patients with Wilson disease complicated by cirrhosis, portal hypertension, and ascites require lifelong copper chelation therapy combined with standard cirrhosis management, and should be promptly evaluated for liver transplantation given the poor prognosis of decompensated disease. 1, 2

Disease-Specific Copper Management

• Continue or initiate copper chelation therapy immediately with penicillamine or trientine, as strict adherence to decoppering agents is essential even in advanced liver disease 2
• Add zinc supplementation as adjunctive therapy 3
• Implement a copper-restricted diet to minimize ongoing hepatic copper accumulation 2, 3
• Avoid alcohol and hepatotoxic drugs to prevent additional liver injury 2

Ascites Management

First-Line Treatment

• Restrict dietary sodium to 2000 mg/day (88 mmol/day) - this translates to a no-added-salt diet with avoidance of precooked meals 4, 5
• Initiate combination diuretic therapy with spironolactone 100 mg plus furosemide 40 mg orally once daily, maintaining the 100:40 mg ratio 4, 5
• Titrate doses upward every 3-5 days (up to spironolactone 400 mg and furosemide 160 mg) if weight loss and natriuresis are inadequate 4
• Fluid restriction is NOT necessary unless serum sodium drops below 120-125 mmol/L 4, 5

Tense Ascites

• Perform initial large-volume paracentesis to rapidly relieve symptoms 6, 4
• Administer albumin 8 g/L of ascites removed when removing >5 L of fluid 5
• For paracentesis <5 L, albumin can be considered in high-risk patients but synthetic plasma expanders (150-200 mL gelofusine/haemaccel) are acceptable 7, 5
• Follow paracentesis with sodium restriction and oral diuretics to prevent reaccumulation 6, 4

Monitoring During Diuretic Therapy

• Monitor serum electrolytes, creatinine, and body weight regularly 4, 5
• Stop diuretics if: serum creatinine >2.0 mg/dL, serum sodium <120 mmol/L, serum potassium >6.0 mmol/L, or hepatic encephalopathy develops 4
• Random urinary sodium >100 mmol/L indicates adequate natriuresis; <0 mmol/L suggests inadequate response 4

Portal Hypertension Complications

Variceal Screening and Management

• Perform endoscopic screening for esophageal varices in all patients with portal hypertension 2, 8
• Initiate non-selective beta-blockers (propranolol or carvedilol) for primary prophylaxis if varices are present 2, 3
• Consider variceal band ligation for large varices at high bleeding risk 2
• In refractory ascites, beta-blockers should not be automatically discontinued but monitor closely for hypotension and renal dysfunction 5

Spontaneous Bacterial Peritonitis (SBP)

• Perform diagnostic paracentesis in all patients with new ascites, hospitalization for any complication, or clinical deterioration 4, 5, 9
• Inoculate ascitic fluid into blood culture bottles at bedside 4, 7
• Diagnose SBP when ascitic fluid neutrophil count >250 cells/mm³ 7, 5, 9
• Treat with cefotaxime or third-generation cephalosporin based on local resistance patterns 5
• Administer albumin 1.5 g/kg within 6 hours, then 1 g/kg on day 3 if creatinine is elevated 5
• Initiate secondary prophylaxis with norfloxacin 400 mg daily or ciprofloxacin 500 mg daily after recovery from SBP 7, 5

Hepatic Encephalopathy

• Treat with lactulose to ensure 2-3 soft bowel movements daily 2
• Add rifaximin 550 mg twice daily for recurrent or persistent encephalopathy 2

Refractory Ascites

Refractory ascites is defined as fluid unresponsive to sodium restriction and maximum diuretic doses (spironolactone 400 mg + furosemide 160 mg), or ascites that recurs rapidly after therapeutic paracentesis. 4

Management Options

• Serial large-volume paracentesis every 2-4 weeks with albumin replacement (8 g/L removed) 4, 5
• Consider TIPSS in carefully selected patients, avoiding those with: age >70 years, bilirubin >50 μmol/L (3 mg/dL), platelets <75×10⁹/L, MELD ≥18, or active hepatic encephalopathy 5
• Avoid NSAIDs as they reduce urinary sodium excretion and can convert diuretic-sensitive to refractory ascites 6, 4

Liver Transplantation Evaluation

All patients with Wilson disease who develop ascites should be considered for liver transplantation evaluation, as this represents decompensated cirrhosis with significantly reduced survival. 6, 7, 5

• The development of ascites reduces 5-year survival from ~80% to ~30% in cirrhosis 9, 10
• Transplantation is curative for both the metabolic defect and liver disease in Wilson disease 5, 2
• Patients with features of clinically significant portal hypertension (varices, splenomegaly, ascites) have increased risk of hepatic decompensation and liver-related mortality 8
• Acute liver failure from Wilson disease (characterized by deep jaundice, hemolysis, low alkaline phosphatase, coagulopathy) requires emergency transplant evaluation with nearly 95% mortality without transplantation 1

Key Monitoring Parameters

• Liver stiffness <15 kPa and platelets ≥150 G/L predict lower risk of decompensation (2.6% at 10 years vs. 8.4%) 8
• Regular screening for hepatocellular carcinoma with ultrasound and AFP every 6 months in cirrhotic patients 9
• Monitor for hepatorenal syndrome development (rising creatinine without other cause) which carries high mortality 2, 10

Common Pitfalls to Avoid

• Never measure serum CA125 in patients with ascites - it is universally elevated and nonspecific, leading to unnecessary gynecologic referrals 4
• Do not restrict fluids unless sodium <120-125 mmol/L - sodium restriction, not fluid restriction, mobilizes ascites 4
• Avoid rapid correction of hyponatremia - chronic hyponatremia in cirrhosis is rarely symptomatic unless <110 mmol/L or rapidly declining 4
• Do not use single-agent furosemide - it is less efficacious than spironolactone and increases hyperkalemia risk 4
• Never discontinue copper chelation even in advanced disease - ongoing copper accumulation worsens liver injury 2